SF3B1 and B-cell chronic lymphocytic leukemia: In the CLL3X trial, the use of reduced-intensity Allo-SCT provided long-term disease control in CLL patients independent of the presence of different adverse prognosticators including NOTCH1, SF3B1, and TP53 mutations (78).